SCHEMBL14964111

SCHEMBL14964111

O=Cc1cncc(CO)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
CYP11B2 P19099 4/20 0.35
CYP11B1 P15538 2/20 0.35
KDM4E B2RXH2 3/20 0.33
DYRK1A Q13627 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
TBXAS1 P24557 2/20 0.32
PTGS2 P35354 1/20 0.30
RAB9A P51151 1/20 0.30
MEN1 O00255 1/20 0.30
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30
HPGD P15428 1/20 0.30
KMT2A Q03164 1/20 0.30
AOX1 Q06278 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5461176 0.81 CA2 (0.33) CYP11B2CYP11B1
SCHEMBL12482370 0.79 LOXL2 (0.35) CYP11B2
SCHEMBL4906652 0.79 ALDH1A1 (0.37) CYP11B2PRMT5WDR77ALDH1A1LMNA
SCHEMBL29955560 0.79 ALDH1A1 (0.37) CYP11B2PRMT5WDR77ALDH1A1LMNA
SCHEMBL29952117 0.79 ALDH1A1 (0.31) MEN1ALDH1A1KMT2A
SCHEMBL29956119 0.79 LOXL2 (0.35) CYP11B2
SCHEMBL29318108 0.79
SCHEMBL29066265 0.78 MKNK1 (0.49) CYP11B2CYP11B1PRMT5WDR77PTGS2
SCHEMBL2728918 0.77 CYP2A6 (0.47) CYP2A6CYP11B2CYP11B1KDM4EDYRK1A
SCHEMBL1663512 0.77 ALDH1A1 (0.36) CYP2A6KDM4EPTGS2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111527079-B 2- [5- (imidazol-1-ylmethyl) pyridin-3-yl ] benzimidazole derivative compound and medicament containing the same 日本医事物理股份有限公司 2023-08-11 CN disclosed
EP-3733661-B1 2-[5-(IMIDAZOLE-1-YLMETHYL)PYRIDINE-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICINE INCLUDING SAME NIHON MEDIPHYSICS CO LTD (JP) 2023-03-15 EP disclosed
US-11266753-B2 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same NIHON MEDI-PHYSICS CO., LTD. (JP) 2022-03-08 US disclosed
US-20210060186-A1 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME NIHON MEDI-PHYSICS CO., LTD. (JP) 2021-03-04 US disclosed
US-20210060186-A1 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME NIHON MEDI-PHYSICS CO., LTD. (JP) 2021-03-04 US disclosed
EP-3733661-A1 2-[5-(IMIDAZOLE-1-YLMETHYL)PYRIDINE-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICINE INCLUDING SAME Nihon Medi-Physics Co., Ltd (JP) 2020-11-04 EP disclosed
EP-3162802-B1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME NIHON MEDIPHYSICS CO LTD (JP) 2020-08-19 EP disclosed
EP-3162802-B1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME NIHON MEDIPHYSICS CO LTD (JP) 2020-08-19 EP disclosed
CN-111527079-A 2- [5- (imidazol-1-ylmethyl) pyridin-3-yl ] benzimidazole derivative compound and medicine comprising the same 日本医事物理股份有限公司 2020-08-11 CN disclosed
WO-2020085238-A1 SALT OF RADIOACTIVE FLUORINE-LABELED PRECURSOR COMPOUND 日本メジフィジックス株式会社 2020-04-30 WO disclosed
EP-3162802-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME Nihon Medi-Physics Co., Ltd. (JP) 2017-05-03 EP disclosed
EP-3162802-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME Nihon Medi-Physics Co., Ltd. (JP) 2017-05-03 EP disclosed
US-9637491-B2 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH (DE) 2017-05-02 US disclosed
CN-106458995-A 2-(3-pyridinyl)-1H-benzimidazole derivative compound and medicine containing same 日本医事物理股份有限公司 2017-02-22 CN disclosed
WO-2015199205-A1 2-(3-PYRIDINYL)-1H-BENZIMIDAZOLE DERIVATIVE COMPOUND AND MEDICINE CONTAINING SAME 日本メジフィジックス株式会社 2015-12-30 WO disclosed
US-9212138-B2 Use of derivatives of indoles for the treatment of cancer COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2015-12-15 US disclosed
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2015-09-24 US disclosed
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-08-21 US disclosed
WO-2014060112-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2014-04-24 WO disclosed
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266882-A1 PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS LRRK2, MYLK2, MYLK CYP2A6 3749/4885CYP11B2 1788/4885CYP11B1 1981/4885
US-20210060186-A1 2-[5-(IMIDAZOL-1-YLMETHYL)PYRIDIN-3-YL]BENZIMIDAZOLE DERIVATIVE COMPOUND, AND MEDICAMENT INCLUDING SAME NPM1, ABL1, FLI1 CYP2A6 1579/4885CYP11B2 72/4885CYP11B1 167/4885
US-20140235654-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT CYP2A6 466/4885CYP11B2 51/4885CYP11B1 70/4885
US-20130131084-A1 USE OF DERIVATIVES OF INDOLES FOR THE TREATMENT OF CANCER IDO1, IDO2, INMT CYP2A6 466/4885CYP11B2 51/4885CYP11B1 70/4885
US-11266753-B2 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same NPM1, XDH, ABL1 CYP2A6 1236/4885CYP11B2 17/4885CYP11B1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.